|
Due to its convenience, more than 4 million women have used Johnson & Johnson’s Ortho Evra birth control patch since it debuted in 2002. However, women who use the patch are three times more likely to suffer blood clots or other Ortho Evra side effects than users of oral contraceptive. Many young women have died as a result of blood clots, heart attack, strokes or other side effects of Ortho Evra.
Women who use the Ortho Evra patch receive a dose of estrogen that is 60% higher than that of birth control pills. When too much estrogen enters a woman's body, it can lead to serious birth control patch side effects. These Ortho Evra side effects include weight gain, blood clots, strokes, deep vein thrombosis, pulmonary embolisms and even death.
On September 20, 2006, results of a new study were released that confirmed previous studies showing an increased risk of blood clots associated with the use of Ortho Evra versus oral contraceptives. The study found that women using Ortho Evra were twice as likely to develop blood clots as those using oral contraceptive pills. As a result, the FDA has asked Ortho McNeil Pharmaceuticals, a division of Johnson & Johnson, to update the safety label on Ortho Evra to warn users about the risk of blood clots, heart attacks and strokes.
In 2005, the FDA stated that women using Ortho Evra are exposed to approximately 60 percent more estrogen than those who use oral contraceptive pills. It is believed that the difference in exposure is related to the delivery mechanism of the birth control patch. Hormones in birth control pills are partially diluted by the digestive system. However, hormones in Ortho Evra are absorbed directly into the blood stream, which causes a higher concentration of the medication to enter a patient’s body. It is believed that high levels of estrogen can greatly increase the risk of developing blood clots, heart attacks, strokes and other serious injuries.
Approximately 4 million women have used the Ortho Evra Patch since it went on sale in 2002. As of November 2005, the FDA had received twenty-one reports of life-threatening blood clots and other ailments associated with the use of Ortho Evra. FDA records obtained by the Associated Press showed that seventeen patch users between the ages of 17 and 30 suffered fatal heart attacks, blood clots and possible strokes since August 2002.
The first fatality publicly blamed on the Ortho Evra patch was in April 2005, when a Manhattan fashion student collapsed in a New York City subway station. An autopsy found that a blood clot had moved into the victim's lung, and the medical examiner ruled that the clot was a side effect of Ortho Evra. The news of this young woman’s death became front page headlines throughout New York.
The manufacturers of Ortho Evra have aggressively marketed the patch as a convenient alternative to oral birth control pills. The drug’s original safety label stated that the patch's health risks were similar to those related to oral contraceptives, even though a recent whistleblower suit alleges that the company was well aware that the birth control patch could cause high rates of blood clots.
Morris & Associates is aggressively representing women injured by Ortho Evra. Morris & Associates is filling Ortho Evra lawsuits on behalf of women who suffered heart attacks, strokes, blood clots and other serious injuries after using Ortho Evra. If you or a loved one were injured while using Ortho Evra, contact Attorney Daniel E. Morris of Morris & Associates today for a free case evaluation. Please complete a case evaluation inquiry on this web-site, or call 662.846.6691 to speak with an attorney today for a free, no-cost no-obligation evaluation of your case.
NuvaRing is the trade name for a combined hormonal contraceptive ring manufactured by Organon that is available by prescription. It is a flexible plastic ring that releases a low dose of a progestin and an estrogen over 3 weeks.
NuvaRing was first approved in The Netherlands on February 14, 2001, then by all 14 other countries then in the European Union on June 12, 2001, and in the United States by the FDA on October 3, 2001. NuvaRing was first marketed in the United States in July 2002, followed by several European countries in late 2002. In March 2007, Organon announced the market launch of NuvaRing in Australia, bringing the total number of countries where NuvaRing is available to 32. NuvaRing is currently used by approximately 1.5 million women worldwide.
NuvaRing stroke and NuvaRing blood clot side effects have been reported by women using this relatively new form of birth control. Strokes and blood clots are being linked to third-generation contraceptives containing desogestrel. Given the increased risk of thromboembolotic side effects there are questions whether patients were adequately warned about the potential risks and complications associated with NuvaRing.
NuvaRing pulmonary embolism, also referred to as NuvaRing PE, is a serious side effect reported by women using this third-generation contraceptive. Venous thrombosis events have been linked to NuvaRing. Pulmonary embolism (PE), deep vein thrombosis (DVT), and ischemic strokes are some of the side effects being associated with NuvaRing.
If you or a loved one has suffered from any of the harmful side effects of Nuva Ring such as blood clots, stroke or heart attack you may be entitled to file a Nuva Ring lawsuit against the manufacturer. A NuvaRing Lawyer can help evaluate your claim. Many women around the United States have suffered from the dangerous side effects of NuvaRing birth control. Unfortunately, most people don't know that they may have important legal rights.
If you or a loved one has suffered serious side effects while using NuvaRing, contact Attorney Daniel E. Morris of Morris & Associates today for a free case evaluation. Please complete a case evaluation inquiry on this web-site, or call 662.846.6691 to speak with an attorney today for a free, no-cost no-obligation evaluation of your case.
Contact Us Now!
|
